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rsitaCord blood transplantation (CBT) from an unrelated donor is recognized as one of the major treatment modal-
ities in allogeneic stem cell transplantation (SCT) for children with hematologic malignancies. We analyzed the
clinical outcomes of CBT for children with acute lymphoblastic leukemia (ALL) in Japan and identified the risk
factors for the transplant outcomes. From 1997 to 2006, 332 children with ALL underwent CBT from unrelated
donors, 270 of which had no prior transplant. Their disease statuses at transplant were first complete remission
(CR) (n5 120), secondCR (n5 71), andmore advanced stages (n5 75). As preconditioning for SCT, total body
irradiation (TBI) was given to 194 patients and, for the prophylaxis of graft-versus-host disease (GVHD), meth-
otrexate (MTX) was given to 159 patients. The cumulative incidents of neutrophil and platelet recovery (.20 K)
were 88.5% and78.4%, respectively. The incidents of grade II-IV, III-IVacuteGVHD(aGVHD), and chronicGVHD
(cGVHD) were 45.6%, 20.4%, and 19.2%, respectively, and treatment-related mortality was 22.6%. The 5-year
event-free survival (EFS) and overall survival (OS) at CR1, CR2, and advanced status were 47.4%, 45.5%,
15.0%, and 63.7%, 59.7%, and 20.7%, respectively. Multivariate analysis revealed that MTXwith calcineurin inhib-
itor (CNI) was associated with decreased incidence of grade II-IVGVHD (CNI alone: hazard ratio [HR]5 1.74,
95% confidence interval [CI]5 1.06-2.83, P5.027; CNI1 prednisolone (PSL), HR5 1.61, 95%CI5 1.03-2.50, P
5 .036), III-IVaGVHD (CNI alone:HR5 3.02, 95%CI5 1.55-5.91, P5 0.001; CNI1 PSL, HR5 1.89, 95%CI5
0.93-3.83, P5 .078), or cGVHD (CNI alone: HR5 1.78, 95% CI5 0.83-3.82, P5 .143; CNI1 PSL, HR5 2.44,
95% CI5 1.24-4.82, P5.01), compared with CNI alone or CNI1 PSL. At an advanced stage of disease, GVHD
prophylaxis withMTX1CNI is associatedwith improvedOS comparedwithCNI alone (CNI alone:HR5 3.20,
95%CI5 1.43-7.15, P5.005;CNI1 PSL,HR5 1.47, CI5 0.67-3.20, P5.332).Our retrospective study showed
that CBT for children with ALL is feasible and GVHD prophylaxis with MTX1CNI is associatedwith significant
favorable outcomes in prevention of aGVHD and cGVHD as well as survival advantage in advanced cases.
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Multiagent chemotherapy for children with acute
lymphoblastic leukemia (ALL) has achieved excellent
clinical outcomes in recent years [1,2]. However, those
patients who relapsed during or after chemotherapy or
those with very high-risk features, such as Philadelphia
chromosome-positive ALL (Ph1ALL) or infant
ALL with mixed lineage leukemia (MLL) gene rear-
rangement, are proposed as candidates for allogeneic
stem cell transplantation (SCT) [3-6] at their first
remission. Patients and donors are required to be
compatible in terms of human leukocyte antigen
(HLA) for better transplant outcome and, if they
lack an HLA-identical related donor, they have op-
tions of alternative donors, such as bone marrow
transplantation (BMT), peripheral blood stem cell
transplantation (PBSCT), cord blood transplantation
(CBT) from an unrelated donor, or transplantation
from an HLA-haploidentical family donor [7-9].
Out of these four treatment modalities, CBT has
advantages such as immediate availability of a CB
unit for an urgent transplant, lower risks of severe
acute and chronic graft-versus-host disease (aGVHD,
cGVHD), and a less stringent requirement of HLA
compatibility than unrelated or haploidentical BMT.
In Japan, the Japan Cord Blood Bank Network
(JCBBN) was established in 1999, and 11 local cord
blood banks are affiliated to JCBBN where more
than 7000 CBT were performed by the end of
2010. Here, we report the clinical outcomes and risk
factors of children with ALL who underwent CBT
in Japan.PATIENTS AND METHODS
Patient and Donor Characteristics
From 1997 to 2006, 332 unrelated CBT were
performed for children with ALL and 270 transplan-
tations were undertaken as the first SCT in Japan.
Because the overall survival (OS) of patients who un-
derwent transplantation as the first SCT was signifi-
cantly better than that of those with prior SCT
(50.3% vs 12.7%, P\ .001), we restricted this analy-
sis to only patients with no prior SCT in order to in-
terpret the exact risk factors of CBT. The patient and
donor characteristics are shown in Table 1. Patients
transplanted at first complete remission (CR1) (n 5
120) include 41 infant ALL and 17 patients with Ph
1ALL.
TheHLA typing of cord blood units was performed
in each CB bank by low-resolution molecular typing
of HLA-A and B, combined with high-resolution
molecular typing of DRB1. The high-resolution mo-
lecular typing for 3 loci of HLA-A, B, and DRB1 was
performed in 187 patients.In JCBBN, CB units of 0 to 2 HLA antigen mis-
matches with the patient were allowed for transplanta-
tion, and the minimum number of nucleated cells
recommended for transplantation was 2  107/kg of
patient body weight at cryopreservation.
Transplantation
All CB units were provided from the 11 local CB
banks affiliated to JCBBN, and all transplant institu-
tions were required to meet the minimum require-
ments of JCBBN in terms of experience of allogeneic
SCT. The numbers of transplanted cells, precondi-
tioning, as well as GVHD prophylaxis are shown in
Table 1. Supportive care after transplantation, such
as gut decontamination, empirical administration of
antibiotics, prophylaxis or treatment of cytomegalovi-
rus (CMV) infection, was performed according to each
institutional protocol. Grading of GVHD was per-
formed according to the standard criteria [10].
Definition and Statistics
The median duration of follow-up was 438 days
(range: 10-3293 days). In this study, rates of neutro-
phil and platelet engraftment, incidents of aGVHD
and cGVHD, leukemic relapse, nonrelapse mortality
(NRM), and probabilities of event-free survival
(EFS) and OS were analyzed. The variables evaluated
included recipient age, sex, sex mismatch, disease
status at transplants (CR1/CR2 vs advanced disease),
ABO compatibility, HLA matching by low- and
high-resolution typing, number of nucleated
cells, colony-forming unit-granulocyte-macrophage
(CFU-GM) and CD34-positive cells of the cord
blood units at cryopreservation conditioning
regimens with total body irradiation (TBI), adminis-
tration of granulocyte-colony stimulating factor
(G-CSF), GVHD prophylaxis (calcineurin inhibitor
[CNI] alone, CNI 1 methotrexate [MTX] versus
CNI 1 prednisolone [PSL]), mixed lineage leukemia
(MLL) gene rearrangement, t(4;11), and transplanta-
tion year. Because the information of high-resolution
DNA typing was only available for a limited number
of patients, it was not included in the multivariate
analysis. The day of neutrophil engraftment was
defined as the first day of 3 consecutive days with
absolute neutrophil count (ANC) $500/mm3, and
that of platelet engraftment was the first day of plate-
let count over 20,000/mm3 without transfusion. The
treatment-related mortality was defined as all causes
of nonleukemic deaths after transplantation. The
EFS was defined as patients who are alive in CR
with engraftment. The probabilities of OS and EFS
were calculated by the method of Kaplan and Meier.
The log-rank test was used for group comparisons.
Time-to-event outcomes for neutrophil and platelet
engraftment, treatment-related mortality, relapse,
Table 1. Patient and Donor Characteristics
Total Number of Patients 270
Age (year) median (range) 5 (0-15)
Body weight (kg) median (range) 18 (4-60)
Sex male/female 156/114
Duration from diagnosis to transplantation (days) median (range) 249 (94-3670)
Disease status at transplantation (patients) CR1 120
CR2 71
advanced 75
unknown 4
Cytogenetics (patients) Philadelphia chromosome 31
MLL gene rearrangement 73
t(4;11) 40
Preparative regimen (patients) TBI regimen 194
TBI + CY + VP16 68
TBI + CY ± others 67
TBI + L-PAM ± others 56
Others 3
non-TBI regimen 76
BU + CY ± others 55
Others 21
G-CSF (patients) + 249
2 21
GVHD prophylaxis (pts) CNI only cyclosporine 29
tacrolimus 12
CNI + MTX cyclosporine + MTX 83
tacrolimus + MTX 66
CNI + PSL cyclosporine + PSL 36
tacrolimus + PSL 11
ATG + CNI ± MTX 7
others 15
none 11
Number of cells at cryopreservation, median (range) Nucleated cell (107/kg) (n 5 270) 5.00 (1.35-24.91)
CFU-GM (103/kg) (n 5 258) 34 (0.87-473.2)
CD34 (105/kg) (n 5 207) 1.49 (0.17-15.02)
Blood type of donor and recipient (pts) match 89
minor 77
major 103
unknown 1
Sex of donor and recipient (pts) M to M 78
F to F 64
M to F 50
F to M 78
HLA disparity in low resolution (patients) No. of disparities GVHD direction Rejection direction
0 54 57
1 168 167
2 47 45
unknown 1 1
HLA disparity in high resolution (patients) No. of disparities GVHD direction Rejection direction
0 21 23
1 56 58
2 77 72
3 28 29
4 4 4
5 1 1
unknown 83 83
G-CSF indicates granulocyte-colony stimulating factor; GVHD, graft-versus-host disease; TBI, total body irradiation; CNI, calcineurin inhibitor; MTX,
methotrexate; PSL, prednisolone; CY, cyclophosphamide.
1816 Biol Blood Marrow Transplant 17:1814-1821, 2011K. Kato et al.and GVHD were estimated using cumulative inci-
dence curves. The competing risk of engraftment is
death before engraftment, that of GVHD is death
without GVHD or relapse, and that of relapse is death
without relapse. The Cox proportional-hazards re-
gression model was used for multivariate analysis of
clinical variables. P values\.05 were considered sta-
tistically significant. Risk factors with a P value\.1
in each univariate analysis were included in the multi-
variate analysis. STATA version 10 (Stata Corpora-tion, College Station, TX) and NCSS 2004
(Number Cruncher Statistical Systems, Kaysville,
UT) were used for the statistical analysis of data.RESULTS
Neutrophil Engraftment
Neutrophil engraftment was obtained in 239
patients. The probability of neutrophil engraftment
Biol Blood Marrow Transplant 17:1814-1821, 2011 1817CBT in Unrelated Donors for Children with ALL in Japanwas 88.5% (95% confidence interval [CI], 84.8%-
92.4%) by day 90, and the median number of days to
reach ANC over 500/mm3 was 22. In univariate
analysis, younger versus older than 1 year old (92.3%
vs 87.6%, P 5 .001), higher versus lower than 3 
107/kg of nucleated cells (89.5% vs 84.6%, P 5
.003), higher versus lower than the median number
of CFU-GM (90.8% vs 86.8%, P \ .001),
higher versus lower than the median number of
CD341 cells (1.5  105/kg, 89.7% vs 85.1%, P \
.001), 0-1 versus 2 Ag HLA mismatches in either
GVHD (89.2% vs 85.1%, P 5 .008) or rejection
(90.2% vs 80.0%, P5 .004) direction, allelic 0-1 versus
2 or more HLA mismatches in either GVHD (92.2%
vs 87.3%, P 5 .009) or rejection (92.6% vs 86.8%,
P 5 .006) direction by high-resolution typing, CR1
or CR2 versus advanced status at transplantation
(89.5% vs 85.3%, P 5 .022), and presence versus
absence of G-CSF (91.2% vs 57.1%, P\ .001) were
significantly associated with higher neutrophil
engraftment rate. The presence or absence of MTX
did not affect the neutrophil engraftment (data not
shown). In multivariate analysis, favorable predictive
factors of neutrophil engraftment were higher number
of CD341 cells, administration of G-CSF, and HLA
disparity of 0-1 antigen for rejection direction
(Table 2).
Platelet Engraftment
Platelet engraftment over 20,000/mm3 was ob-
tained in 202 patients, and the probability of platelet
engraftment by day 180 was 78.4%. In univariate
analysis, younger versus older than 1 year old (82.8%
vs 77.1%, P5 .004), higher versus lower than the me-
dian number of nucleated cells (78.8% vs 76.6%, P 5
.008), higher versus lower than the median number of
CFU-GM (82.8% vs 73.7%, P 5 .004), higher versus
lower than the median number of CD341 cells
(84.9% vs 71.8%, P\ .001), disease status of CR1 or
CR2 versus advanced (83.8% vs 63.3%, P \ .001),
and presence versus absence of G-CSF (80.1% vs
57.8%, P 5 .017) were significantly associated with
higher platelet engraftment rate. Multivariate analysis
revealed that a higher number of CD341 cells and
CR1 or CR2 at transplantation were favorable prog-
nostic factors for platelet engraftment (Table 2).
GVHD
The cumulative incidents of grade II-IV and
III-IV aGVHD were 45.6% (95% CI, 40.0%-51.9%)
and 20.4% (95% CI, 16.1%-25.8%), respectively. In
univariate analysis, HLA-mismatched donor versus
matched donor in GVHD direction by low resolution
(49.3% vs 31.5%, P 5 .023) and high resolution
(51.2% vs 14.3%, P 5 .003), and presence versus
absence of TBI (51.6% vs 30.3%, P 5 .003) weresignificantly associated with the development of grade
II-IV aGVHD, and MTX 1 CNI showed a trend of
impact on the development of grade II-IV aGVHD
(40.3% in MTX 1 CNI, 53.7% in CNI alone, and
63.8% in CNI 1 PSL, P5 .096). GVHD prophylaxis
with MTX 1 CNI was the only significant predictive
factor for decreased incidence of grade III-IV
GVHD (14.1% in MTX 1 CNI, 27.7% in CNI 1
PSL and 36.7% in CNI alone, P 5 .011) (Figure 1).
Multivariate analysis revealed that TBI was signifi-
cantly associated with increased incidence of grade
II-IV aGVHD, and GVHD prophylaxis with MTX
1 CNI was significantly associated with decreased in-
cidence of grade II-IV and III-IV aGVHD (Table 2).
The cumulative incidence of the development of
cGVHD was 19.2% (95% CI, 15.0%-24.6%), and
the incidence of cGVHD was significantly reduced
in HLA-matched donor in low resolution for rejection
direction compared with that in the GVHD direction
(12.2% vs 22.6%, P5 .002), as well as GVHDprophy-
laxis with MTX1 CNI compared with that with CNI
alone or CNI 1 PSL (16.1% vs 22.5%, or 29.3%, re-
spectively, P5 .03) (Figure 1). In multivariate analysis,
HLA mismatch for rejection direction in low resolu-
tion and GVHD prophylaxis with CNI 1 PSL were
the significant risk factors for the development of
cGVHD (Table 2). In our study population, only 7 pa-
tients were given anti-T cell globulin (ATG) for
GVHD prophylaxis. The cumulative incidence of
grade II-IV aGVHD and cGVHD in this population
was 14.7%, respectively, and 5 patients died of either
relapse or transplantation-related complications.Transplant-Related Mortality (TRM)
The cumulative incidence of TRM after CBT was
22.6% (95% CI, 17.7%-27.8%). Univariate analysis
showed that HLA mismatch of 2 or more loci versus
0-1 in high-resolution typing for either GVHD
direction (23.2% vs 10.4%, P 5 .03) or rejection di-
rection (23.1% vs 11.2%, P 5 .03), advanced disease
status versus CR1 or CR2 (35.3% versus 17.4%, P\
.001), and GVHD prophylaxis other than MTX 1
CNI (15.1% in MTX 1 CNI, 29.3% in CNI alone,
and 31.4% in CNI 1 PSL, P 5 .01) were signifi-
cantly associated with a higher incidence of TRM.
Multivariate analysis revealed that advanced disease
status at transplantation was a risk factor for TRM
(Table 2).Leukemic Relapse
Eighty-six patients relapsed between 8 and 976
days (median 182) after CBT. The cumulative inci-
dence of leukemic relapse at 3 years was 35.2% (95%
CI, 29.8%-42.1%). Advanced disease versus CR1 or
CR2 (48.8% vs 30.6%, P \ .001) and presence
Table 2. Multivariate Analysis of Risk Factors for Transplantation Outcomes
Variable Hazard Ratio P Value 95% CI
Neutrophil engraftment CD34 (105/kg) <1.5 1
$1.5 1.7 .001 1.26-2.28
G-CSF no 1
yes 3.06 .001 1.60-5.83
HLA disparity in low resolution
(rejection direction)
0-1 1
2 0.62 .024 0.41-0.94
Platelet engraftment ($20,000/mm3) CD34 (105/kg) <1.5 1
$1.5 1.9 .001 1.35-2.66
Disease status CR1, CR2 1
advanced 0.58 .008 0.39-0.87
Acute GVHD ($II) TBI no 1
Yes 1.859 .015 1.13-3.06
GVHD prophyalxis CNI + MTX 1
CNI only 1.74 .027 1.06-2.83
CNI + PSL 1.61 .036 1.03-2.50
Acute GVHD ($III) GVHD prophylaxis CNI + MTX 1
CNI only 3.02 .001 1.55-5.91
CNI + PSL 1.89 .078 0.93-3.83
Chronic GVHD HLA disparity in low resolution
(GVHD direction)
0 1
1,2 2.73 .055 0.98-7.61
GVHD prophylaxis CNI + MTX 1 .029
CNI only 1.777 .143 0.83-3.82
CNI + PSL 2.44 .01 1.24-4.82
Treatment-related mortality Disease status CR1, CR2 1
advanced 2.56 .005 1.33-4.92
Relapse Disease status CR1, CR2 1
advanced 3.16 <.001 2.04-4.89
t(4;11) no 1
yes 1.93 .014 1.14-3.26
Overall survival Disease status CR1, CR2 1
advanced 3.62 <.001 2.44-5.8
Event-free survival Disease status CR1, CR2 1
advanced 2.54 <.001 1.83-3.51
CI indicates confidence interval; G-CSF indicates granulocyte-colony stimulating factor; GVHD, graft-versus-host disease; TBI, total body irradiation;
CNI, calcineurin inhibitor; MTX, methotrexate PSL, prednisolone.
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(48.3% vs 33.1%, P 5 .044) were significantly
associated with leukemic relapse in univariate analysis.
Both of these factors were also significant in multivar-
iate analyses (Table 2).
OS
One hundred fifty-two patients were alive after
CBT, and their median number of days of survival
was 961 (91-3293). The cause of death in 118 patients
included relapse or progressive disease (n5 50), TRM
(n5 66), and unknown reason (n5 2). The probability
of projected 5-year OS for all patients was 50.3%
(95% CI, 43.4%-56.8%), and it was 63.7% in CR1,
59.7% in CR2, and 20.7% at more advanced disease
status (Figure 2). Univariate analysis revealed that
HLA mismatch of$2 versus 0 or 1 for rejection direc-
tion (50.9% vs 66.0%, P 5 .017) in high-resolution
typing, advanced disease versus CR1 or CR2 (20.7%
vs 62.1%, P\ .001), and GVHD prophylaxis of other
than MTX 1 CNI (56.8% in MTX 1 CNI, 43.3% in
CNI alone, and 40.6% in CNI1 PSL, P5 .049) were
significantly associated with OS (Figure 3). In multi-
variate analysis, advanced disease status at transplanta-
tion was the only risk factor for OS.Whenmultivariate
analysis was restricted to the patients with advanceddiseases, OS was significantly superior for patients
with GVHD prophylaxis of MTX 1 CNI than CNI
alone (CNI alone: HR 5 3.20, 95% CI 5 1.43-7.15,
P 5 .005; CNI 1 PSL, HR 5 1.47, CI 5 0.67-3.20,
P 5 .332).EFS
The probability of projected 5-year EFS for all
patients was 38.1% (95% CI, 31.8%-44.4%), and it
was 47.4% in CR1, 45.5% in CR2, and 15.0% at
more advanced disease status. Univariate analysis
revealed that HLA mismatch of 1 or more versus
0 with high-resolution typing in either GVHD direc-
tion (33.9% vs 51.3%, P5 .047) or rejection direction
(31.5% vs 52.9%, P 5 .010), advanced disease status
versus CR1 or CR2 (15.0% vs 46.6%, P\ .001), and
absence versus presence of G-CSF (22.0% vs 39.3%,
P 5 .028) were significantly associated with EFS.
The EFS rates of patients according to the HLA dis-
parity in high-resolution typing in GVHD direction
were 61.9% in 0 of 6 (n 5 21), 47.0% in 1 of 6 (n 5
56), 36.4% in 2 of 6 (n 5 77), and 28.4% in 3 of 6
(n5 28) (P5 .127). Although this was not significant,
the more the HLA disparity increased, the lower the
EFS became. Inmultivariate analysis, advanced disease
Figure 1. Cumulative incidence of aGVHD (grade III-IV) (left) and cGVHD (right). GVHD prophylaxis with CNI1MTX is associated with significantly
lower incidence of aGVHD and cGVHD.
Biol Blood Marrow Transplant 17:1814-1821, 2011 1819CBT in Unrelated Donors for Children with ALL in Japanstatus at transplantation was significantly associated
with lower EFS (Table 2).DISCUSSION
The outcomes of CBT according to the disease
status at transplantation in children with ALL were
reported from a multicenter study of Eurocord. The
disease-free survival (DFS) rates of those patients
transplanted at complete remission and at more ad-
vanced stages were 36%-49% and 10%-18%, respec-
tively [11-13]. In contrast to these multicenter
studies, single or small numbers of institutions report
better results. A study from Minnesota University
reported that the EFS of children with ALL in
standard and high-risk patients are 55% and 32%, re-
spectively [14]. In the Cord Blood Transplantation
(COBLT) study, the OS of children with ALL was
around 60% in first and second remission [15], and
a study in Denver [16] reported DFS of 62%
including standard and high-risk patients. Our study
is a retrospectively reviewed multicenter study with
a large number of children with ALL, and the EFSFigure 2. Probability of overall survival of patients according to disease
status at transplantation. Patients with CR1 and CR2 are associated with
significantly better overall survival compared with patients with ad-
vanced stage.or OS is comparable to that of these single-center
studies.
The relevance of HLA disparity to clinical out-
come in unrelated CBT has been reported by several
investigators. In an International BoneMarrowTrans-
plant Registry (IBMTR) study, the OS of serologically
6/6-matched CBT was significantly better than that of
mismatched CBT, irrespective of the cell dose of the
CB unit [17]. In Eurocord, the serologic disparity of
HLA was reported to be important for engraftment
and relapse but not for GVHD or survival, namely, se-
rologic HLA mismatch reduced the relapse rate after
transplantation. In those studies, HLA disparity in
high resolution did not affect any clinical outcomes
[18]. In our study, HLA disparity in low resolution
affected the neutrophil engraftment and GVHD or
cGVHD but not for relapse and survival. The OS ac-
cording to the HLA disparity in high resolution grad-
ually declined as the HLA disparity increased, even
though this was not statistically significant in univari-
ate analysis.
The different results regarding risk factors for re-
lapse between our data and Eurocordmay be explained
by the difference of the patient population. Our studyFigure 3. Probability of overall survival of patients according to GVHD
prophylaxis. Patients with GVHD prophylaxis of CNI 1 MTX is associ-
ated with significantly better overall survival compared with patients
with CNI alone or CNI 1 PSL.
1820 Biol Blood Marrow Transplant 17:1814-1821, 2011K. Kato et al.was restricted to childhood ALL, whereas Eurocord
included acute myelogenous leukemia (AML) patients
[12,18], for whom a graft-versus-leukemia (GVL)
effect could be more efficient than ALL patients after
allogeneic SCT. Although the implications of the
HLA disparity in high resolution for clinical outcome
are still controversial, future study with a large number
of patients could clarify the relevance of HLA disparity
in high resolution on clinical outcomes.
GVHDprophylaxis afterCBT is still controversial,
and various methods of prophylaxis are applied in each
institution or study group. In the early era of unrelated
CBT, cyclosporine (CsA) and steroids with or without
MTX were given as GVHD prophylaxis [19]. Subse-
quently, MTX was abandoned, and immunosuppres-
sion with CsA and steroids became popular in the
United States andEuropean countries. In their reports,
the incidence of GVHD after CBT is 35% to 44% for
grade II-IV aGVHD, 11% to 27% for grade III-IV
aGVHD, and 9% to 33% for cGVHD [14,20-22],
mostly by prophylaxis with CsA and steroids. GVHD
prophylaxis with CNI alone after CBT was
reportedly complicated with preengraftment immune
reaction [23], but a Japanese retrospective study
showed the superiority of GVHD prophylaxis with 2
agents compared with that of single agent in terms of
DFS for patientswith acute leukemia [24]. In this study,
we found that the use ofMTX showed favorable effects
of significantly lower incidents of aGVHD and
cGVHD, and in advanced cases, better OS was ob-
served without affecting the engraftment or relapse.
In Eurocord, an unfavorable effect of delayed myeloid
engraftment by MTX was reported only in related
CBT but not in unrelated CBT [25,26]. Another
disadvantage of MTX reported by Eurocord was
a higher relapse rate in unrelated CBT for children
with ALL [12]. This unfavorable effect was not ob-
served in our study, and this discrepancy could be ex-
plained by the different proportion of patients who
were given ATG before SCT. In one Eurocord study
for children with ALL, 88% of patients were given
ATG [13], but only 7 of 270 patients (2.6%) were given
ATG in our study. Because ATG reduces the incidence
of aGVHD and cGVHD by purging T cells in vivo
[27],GVHDprophylaxis includingMTXwith orwith-
out ATG needs to be analyzed in terms of transplanta-
tion outcomes including the GVL effect.
In Japan, Narimatsu [28] and Terakura [29] re-
ported thatMTX after CBT reduced the complications
such as preengraftment immune reaction, engraftment
syndrome, and aGVHD, as well as the incidence of
treatment-related mortality and improved survival in
adults. Takahashi also reported superior DFS after
CBT with GVHD prophylaxis of MTX and CsA
[30]. Neither of these studies found any unfavorable ef-
fects caused by MTX in unrelated CBT. In a Japanese
pediatric study of CBT for AML,MTX contributed tolowerTRM [31]. The critical role ofMTX in unrelated
CBT should be emphasized as a key drug in terms of
prophylaxis for GVHD, although transplantation
outcomes according to the dose and frequency of
MTX administration was unable to be analyzed in this
study. In our study, nobody was given mycophenolate
mofetil (MMF), and the combination of CNI 1 MMF
needs to be compared withCNI1MTX in the pediatric
population.
In conclusion, CBT from an unrelated donor is
feasible and effective as a treatment modality for
children with ALL, and GVHD prophylaxis, which
includes MTX, is critical to reduce the incidence of
aGVHD and cGVHD without affecting engraftment,
as well as to achieve better OS in advanced cases.ACKNOWLEDGMENTS
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